4.7 Review

Formulation of Neulasta® (pegfilgrastim)

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 60, Issue 1, Pages 50-58

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2007.04.017

Keywords

r-metHuG-CSF; Neulasta (R) (pegfilgrastim); formulation; PEGylation

Ask authors/readers for more resources

Neulasta (R) (pegfilgrastim) is a PEGylated version of its parent molecule NEUPOGEN (R)) (Filgrastim). This work describes the formulation development for Neulasta (R) (pegfilgrastim), and the analytical techniques used to monitor degradation during these studies. Stability was assessed as a function of pH, protein concentration, buffer type, tonicity modifiers and surfactant concentration under both accelerated conditions and quiescent long-term storage. The stability of Neulasta (R) (pegfilgrastim) to agitation and successive freeze-thaw cycles was also assessed. Neulasta (R) (pegfilgrastim), at a protein concentration of 10 mg/mL formulated in 10 mM acetate, pH 4.0 with 5% sorbitol and 0.004% polysorbate 20, is stable for two years stored at 2-8 degrees C. (c) 2007 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available